SCHEMBL6818684

SCHEMBL6818684

COc1ccn2nc(-c3ccccc3)c(-c3ccc(=O)n(C(C)C)n3)c2c1Br

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.35
TP53 P04637 2/20 0.32
PDE4A P27815 2/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
HRH3 Q9Y5N1 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR3 P22607 1/20 0.32
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
MAPT P10636 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824757 0.87 ADORA1 (0.38) ADORA1TP53PDE4APDE4BPDE4C
SCHEMBL6822091 0.78 ADORA1 (0.41) ADORA1TP53HRH3MEN1ALDH1A1
SCHEMBL6821956 0.78 ADORA1 (0.39) ADORA1TP53HRH3MAPTALDH1A1
SCHEMBL6821959 0.78 ADORA1 (0.42) ADORA1FGFR1FGFR2FGFR3
SCHEMBL6821908 0.77 ADORA1 (0.38) ADORA1HRH3MAPTALDH1A1SMN1; SMN2
SCHEMBL6822356 0.77 ADORA1 (0.43) ADORA1TP53MEN1KMT2ASMN1; SMN2
SCHEMBL7039587 0.75 ADORA1 (0.57) ADORA1PDE4B
SCHEMBL6822507 0.74 HTR7 (0.38) ADORA1TP53HRH3ALDH1A1SMN1; SMN2
SCHEMBL6825199 0.74 CASR (0.41) ADORA1HRH3FGFR1FGFR2FGFR3
SCHEMBL6822067 0.73 ADORA1 (0.43) ADORA1TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 ADORA1 22/4885TP53 4085/4885PDE4A 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.